dr. hammers discusses combining ido and pd-1 inhibitors in rcc
Published 6 years ago • 118 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
1:37
dr. hammers on combinations of ido and pd-1 inhibitors in rcc
-
1:21
dr. hammers on combination of vaccines and immune checkpoint inhibitors in rcc
-
0:55
dr. luke discusses pd-1 plus ido inhibitors in melanoma
-
0:56
dr. hammers on next steps with immunotherapy in rcc
-
1:27
dr. hammers on nivolumab/ipilimumab data in rcc
-
1:21
dr. hammers on the long-term benefits of the checkmate-214 study in rcc
-
7:06
pd-1 inhibition in metastatic renal cell carcinoma
-
1:40
dr. luke on combining an ido inhibitor with nivolumab in advanced cancers
-
38:09
understanding and working with new immunotherapeutic and targeted management models in advanced rcc
-
1:42
dr. hammers on combination strategies in kidney cancer
-
6:44
immune checkpoint inhibition in renal cell carcinoma
-
1:17
dr. hammers on the future of immunotherapy in rcc
-
2:18
dr hans hammers discusses highlights from the thirteenth international kidney cancer symposium
-
3:09
dr hans hammers discusses the clinical trial of nivolumab plus ipilimumab in renal cell carcinoma
-
5:07
ido inhibitors in metastatic melanoma
-
1:49
dr. choueiri on subsequent combo therapy after pd-1/pd-l1 blockade in rcc
-
1:37
dr. choueiri on synergy between immunotherapy and vegf inhibitors in rcc
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
1:20
dr. hammers on immunotherapy combinations in kidney cancer